AVR RD 02

Drug Profile

AVR RD 02

Alternative Names: AVR-RD-02

Latest Information Update: 28 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lund University
  • Developer AVROBIO
  • Class Gene therapies
  • Mechanism of Action Cell replacements; Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gaucher's disease

Most Recent Events

  • 09 Aug 2018 AVROBIO plans to file an clinical trial application (CTA) for AVR RD 02 in Gaucher disease in second half of 2018
  • 01 Feb 2018 AVROBIO plans a phase I/II trial for Gaucher's disease in USA in June 2019
  • 22 Mar 2017 Preclinical trials in Gaucher's disease in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top